Indivior (INDV) Expected to Announce Quarterly Earnings on Thursday

Indivior (NASDAQ:INDV) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, July 24th. Analysts expect the company to announce earnings of $0.25 per share for the quarter. Indivior has set its FY 2025 guidance at EPS.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.19. Indivior had a negative net margin of 4.02% and a negative return on equity of 97.29%. The company had revenue of $266.00 million for the quarter, compared to the consensus estimate of $240.13 million. On average, analysts expect Indivior to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Indivior Trading Up 1.4%

Shares of INDV stock opened at $15.60 on Thursday. Indivior has a twelve month low of $7.33 and a twelve month high of $15.91. The business’s 50 day moving average is $13.39 and its two-hundred day moving average is $11.46.

Institutional Investors Weigh In On Indivior

A hedge fund recently raised its stake in Indivior stock. Jane Street Group LLC grew its position in Indivior PLC (NASDAQ:INDV) by 2,597.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 995,013 shares of the company’s stock after acquiring an additional 958,132 shares during the quarter. Jane Street Group LLC owned approximately 0.72% of Indivior worth $9,327,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 60.33% of the company’s stock.

Analysts Set New Price Targets

INDV has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Indivior from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 21st. Craig Hallum increased their price target on shares of Indivior from $15.00 to $22.00 and gave the company a “buy” rating in a report on Monday, June 30th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $17.00.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.